Toxicokinetics of resveratrol in dogs

Crowell, James A.; McCormick, David; Cwik, Michael; Kapetanović, Izet M.

doi:10.1016/j.toxlet.2007.05.278

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are very few studies on the bioavailability of resveratrol in dogs. However, in two studies examining the toxicity of resveratrol in dogs, doses of 200 to 1200mg/kg administered orally in capsules resulted in detectable levels of resveratrol and its metabolites in plasma [26,27]. A biological effect on weight gain, body condition, body fat and energy consumption was evident in our dogs at 60mg/dog, indicating that resveratrol was bioavailable at this lower dose in dogs (unpublished data 2 ).…”

Section: Discussionmentioning

confidence: 68%

Effect of Resveratrol Supplementation on the Performance of Dogs in an Eight-Arm Radial Maze

Story¹

2012

TONUTRJ

View full text Add to dashboard Cite

Abstract:Resveratrol supplements are marketed on the premise they enhance cognitive function. We explored effects of resveratrol supplementation on cognitive function, in the absence of pathology, by assessing effects of resveratrol on the performance of young, healthy, recently gonadectomised dogs in an eight-arm radial maze. Effects of gonadectomy on cognition were also assessed. Performances of untreated intact dogs, resveratrol-treated gonadectomised dogs (60mg/day of resveratrol orally) and placebo-treated gonadectomised dogs were compared in three phases. Dogs received the placebo or resveratrol for two to four weeks before testing began. In phase one, untreated intact (n = 16), resveratrol-treated gonadectomised (n = 6) and placebo-treated gonadectomised dogs (n = 5) were allowed to choose all maze arms they entered. In phase two, untreated intact (n = 15), resveratrol-treated gonadectomised (n = 6) and placebo-treated gonadectomised dogs (n = 5) entered four predetermined arms and then made four free choices from all eight arms. In phase three, a subset of dogs previously tested as untreated intact dogs in phases one and two were tested. In phase three, placebotreated gonadectomised (n = 6) and resveratrol-treated gonadectomised dogs (n = 6) entered seven predetermined arms and then had free choice between a previously opened arm and the unopened arm. Performance in the maze did not differ significantly between gonadectomised dogs receiving the placebo and gonadectomised dogs receiving resveratrol or between untreated intact dogs and gonadectomised dogs receiving the placebo. We conclude that resveratrol treatment does not improve (and gonadectomy does not impair) the aspects of cognitive function that were tested by the radial arm maze trials in young, healthy dogs receiving extensive handling and environmental/behavioural enrichment.

show abstract

Section: Discussionmentioning

confidence: 68%